RxDoctor Payments Data

Natalie Spiller, PA

Physician Assistant · Herrin, ILNPI 1942550272

Payments from drug & device makers

$6,432in general payments, 2019–2025

Across 295 payments — averaging $21.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$1K
  • Amgen$1K
  • AbbVie$664
  • Lilly USA, LLC$432
  • Novartis$415
  • Incyte Corporation$364
  • plus $2K from 14 others

What the payments were for

  • Consulting fees$85013%
  • Food & beverage$4,93977%
  • Education$64310%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,432 in reported general payments places this provider in the 95th percentile of 3,912 physician assistant providers in Illinois.

See all physician assistant providers in Illinois

Medicare billing

Part B allowed, 2024
$214,256
Medicare patients
902
Services billed
3,706

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast56$246,991
Cosentyx Sensoready (2 Pens)Secukinumab32$228,489
Humira(Cf) PenAdalimumab30$227,456
Dupixent SyringeDupilumab53$226,063
Dupixent PenDupilumab42$165,435
SotyktuDeucravacitinib11$87,025
Calcipotriene33$4,618
Betamethasone Valerate80$3,194
Clobetasol Propionate62$2,635
Fluorouracil37$2,522
Fluocinonide48$2,480
Metronidazole28$2,321
Ketoconazole107$1,593
Clindamycin Phosphate41$1,549
Tacrolimus14$1,345

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$1,025$246,99156 claims
E.r. Squibb & Sons, L.L.C.Sotyktu$226$87,02511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,912 physician assistant providers in Illinois.

Other physician assistant in Herrin

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →